Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230586 | 0.89 | DRD1 (0.44) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL1229166 | 0.89 | DRD1 (0.44) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL1549193 | 0.81 | ALDH1A1 (0.43) | KCNH2SCN10ASCN5ASCN2AALDH1A1 | |
| SCHEMBL505301 | 0.79 | DRD1 (0.56) | SCN5ACA12CA9NOTUMAURKA | |
| SCHEMBL9062115 | 0.79 | RXRA (0.48) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL12614281 | 0.79 | VNN1 (0.52) | SCN10AADORA3AURKATPX2L3MBTL1 | |
| SCHEMBL508451 | 0.78 | SCN10A (0.47) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL3542039 | 0.78 | KIF11 (0.42) | SCN2AALDH1A1L3MBTL1KIF11 | |
| SCHEMBL1228649 | 0.78 | AURKA (0.49) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL19514109 | 0.77 | SCN10A (0.47) | KCNH2SCN10ASCN5ASCN1ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155756-B2 | Pyrazolo[1,5-A]pyridine compounds and use thereof | GUANGZHOU EGGBIO CO., LTD. (CN) | 2018-12-18 | — | — | US | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| US-9169216-B2 | Method for preparation of 5-substituted pyrimidines | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140121375-A1 | METHOD FOR PREPARATION OF 5-SUBSTITUTED PYRIMIDINES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-01 | — | — | US | disclosed |
| CN-102753558-A | Nitroimidazooxazines and their use in antitubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEV | 2012-10-24 | — | — | CN | disclosed |
| WO-2012128965-A2 | METHOD FOR PREPARATION OF 5-SUBSTITUTED PYRIMIDINES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | ABCG2, ABCC1, PNPO | KCNH2 2839/4885SCN10A 3962/4885SCN5A 2021/4885 |
| US-10155756-B2 | Pyrazolo[1,5-A]pyridine compounds and use thereof | ABCG2, ABCC1, PNPO | KCNH2 2839/4885SCN10A 3962/4885SCN5A 2021/4885 |
| US-20140121375-A1 | METHOD FOR PREPARATION OF 5-SUBSTITUTED PYRIMIDINES | DPYD, TYMP, DUT | KCNH2 3169/4885SCN10A 4810/4885SCN5A 901/4885 |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | KCNH2 3157/4885SCN10A 4460/4885SCN5A 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.